We have some news to share: repertoire.com/about/press-re…

The immune system usually controls infections caused by #HPV. Persistent, untreated infection by a high-risk genotype HPV can cause cancer. On #InternationalHPVAwarenessDay we’re raising awareness of this link as we continue to work to advance treatments for HPV-positive cancers.

We have some news to share: repertoire.com/about/press-re…

At #PEGS22 we’re sharing the latest data about our injectable CD8-targeted IL-12 and the immunologically “silent” CD8 antibodies we identified to enable T cell targeted cytokines. We look forward to connecting and exchanging ideas at the summit. pegsummit.com

This June we celebrate #PrideMonth and share our gratitude for the many people whose individuality strengthens our team. Diversity in the immune system keeps us healthy. Diversity in our community makes us stronger. We are proud to stand in solidarity with the LGBTQ+ community.

Today, we will be presenting new data at the FOCIS 2022 Annual Meeting. Using our DECODE™ platform, Repertoire scientists discovered previously unidentified epitopes involved in the pathogenesis of type 1 diabetes. Learn more: bit.ly/3zZiWYs #FOCIS2022

As #PrideMonth draws to a close, it is important to recognize that, today and every day, we support a culture in which diverse voices are heard, respected, and supported within our organization.

Our research collaboration with Memorial Sloan Kettering Cancer Center uses DECODE™ to identify TCR-antigen pairs activated when the immune system successfully fights HPV+ cancers. Learn how this may help improve treatment outcomes and potentially lead to new medicines: bit.ly/3aAC9VV

We stepped outside the lab to enjoy what remains of the summer season! Our Repertoire team got together to relax and recharge along the Charles River at this year’s summer outing.

Tomorrow is #WorldCancerResearchDay. We are proud to be part of a global community of scientists, researchers and organizations committed to research and development of treatments for the people affected by this disease.

At this year’s Society for Immunotherapy of Cancer annual meeting in Boston, we will present data demonstrating how our DECODE platform characterizes novel targets that may lead to new immunotherapies. Learn more about our data presentations here: bit.ly/3SNZ7cK #SITC22 #immunotherapy #cancer

Today at #SITC222, we presented research conducted with our DECODE™ platform that identified highly prevalent immunotherapeutic targets in HPV-positive cancers, unlocking pathways for potential therapeutics Learn more. repertoire.com/about/press-re…

Today, Anthony Coyle, our Head of Research and Development, will present at the FASEB Immune Repertoire Decoding Conference. We look forward to sharing our research in #immunotherapy using the DECODE™ platform. Learn more about the presentation here: bit.ly/3HMYSuq

We are excited to announce we have entered into a multi-year strategic collaboration with Bristol Myers Squibb to develop tolerizing vaccines for up to three #autoimmune diseases. Read more: bit.ly/3UiabRG

Read about our collaboration with Bristol Myers Squibb to develop tolerizing vaccines for #autoimmune diseases. bit.ly/3UiabRG

Tolerizing vaccines are designed to restore immune balance in patients with #autoimmune diseases. Learn more about how we are developing our #mRNA tolerizing vaccines using our proprietary DECODE™ platform: repertoire.com/platforms/appr…

Our multi-year strategic collaboration with Bristol Myers Squibb aims to develop efficacious, selective, and durable treatments for patients suffering from #autoimmune disease by resetting the immune system. More here: bit.ly/3UiabRG

Learn more about how we're developing mRNA tolerizing vaccines using our DECODE platform and our recently announced collaboration with Bristol Myers Squibb in this Q&A with Repertoire's President and Head of R&D Anthony Coyle: flagshippioneering.com/stories/q-a-wi…

Today we have entered into a collaboration and license agreement with Genentech to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease. Learn more: prnewswire.com/news-releases/…

Repertoire is pleased to announce the appointment of oncology expert and industry veteran Robert Andtbacka, MD, CM, FACS, FRCSC, as Chief Medical Officer, as our team advances a TCR-bispecific development candidate toward the clinic. repertoire.com/about/press-re…